The purpose of this study is to examine the blood levels of two doses of MAP0010 (a
corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with
twice daily dosing over 7 days.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Collaborator:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan